Resources

Country- and Community-Led Scale-Up of Accessible, Integrated, and Family-Centered EVT Plus Services for a Healthy Start (SAFEStart+)While childhood survival rates have significantly improved in the past decade, every year, approximately five million children die before their fifth birthday—almost half are newborns in their first month of life. Vertical transmission of HIV, syphilis, hepatitis B, and Chagas disease is a leading cause of preventable stillbirth and child mortality. Timely diagnosis and treatment of these infections are critical to protect the health and well-being of women, infants, and young children.Through partnership and funding from Unitaid, PATH and the project’s co-leads, the International Community of Women living with HIV Eastern Africa and the World Hepatitis Alliance, are leading a four-year project designed for maximum reach and impact: SAFEStart+. This project is accelerating demand and adoption of evidence-based approaches and integrated delivery strategies to eliminate vertical transmission of HIV, syphilis, hepatitis B, and Chagas disease.SAFEStart+ is supporting countries and communities to design and scale integrated, people-centered services that meet local needs. This includes expanding access to new diagnostics that can detect multiple infections with a single test and reinforcing antenatal care services to deliver preventive treatment when it matters most.

This is a simple, Excel-based tool for assessing and comparing costs of rotavirus vaccination programs with each rotavirus vaccine product available in the global market. It aims to help national-level policymakers specifically in countries eligible for support from Gavi, the Vaccine Alliance, compare products and estimate vaccination program costs for different rotavirus vaccines, exploring up to four different vaccine options at a time.The tool calculates cold chain volume and costs annually and for a total period of five years. Cost estimates are composed of vaccine cost (i.e., vaccine and supplies procurement and international shipping) and vaccination program costs (i.e., vaccine cost and cost of delivery). Cost estimates are provided separately for the country perspective and the combined country and Gavi perspective.It is important to note that cost is only one consideration when selecting a rotavirus vaccine product, and users involved in decision-making around new vaccine introduction/switch or product selection should always consider other dimensions as well. This model is meant to provide insights into the potential costs of alternative product choices and should not replace detailed budget planning once a product has been selected.A user guide is included in the file on a tab labeled “READ ME FIRST” which provides detailed instructions on how to use the tool and interpret the results. The tool is available to download in multiple languages. Please be sure to check out this seven-minute tutorial video, which is in English, with French and Spanish subtitled versions also available. If you have additional questions or need support, contact PATH’s Health Economics & Outcomes Research team: HEOR@path.org.NOTE: Please refer to this web page for the most up-to-date version of the calculator, which is periodically updated to reflect the evolving vaccine landscape.

This factsheet focuses on the development of BABE—a low-cost bubble continuous positive airway pressure (bCPAP) device with oxygen blenders to help babies with respiratory distress syndrome. BABE is designed to provide bCPAP therapy to preterm newborns without requiring a power source (i.e., electricity or battery) or medical-grade compressed air.

Part 1 of “Rethinking the future of maternal and child survival in Africa in a changing aid landscape,” the newest edition to our Africa regional MNCH advocacy dialogues series, was held on June 26, 2025, featuring a moderated discussion with panelists from PATH, UNICEF, Africa Union Commission, Umzanyana Birth Services, Reproductive Health Division, and MSD for Mothers. The resource below is one of the presentations from the webinar. In the coming weeks we will share the recording for the webinar as well.

According to the World Health Organization, medical oxygen is one of the key essential medicines required for multiple health conditions, including asthma, heart failure, and various newborn complications. Over the last decade, the Ugandan government has worked to improve access to medical oxygen. The National Scale Up of Medical Oxygen Implementation Plan (2018–2022), launched in 2019, guided this progress, which included increasing manufacturing capacity and installing oxygen plants at referral hospitals.